+91-8668442535

Premature Ejaculation Treatment Market By Drug Class (Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors, Others), By Route Of Administration (Oral Route, Topical Route) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

The premature ejaculation treatment market is expected to reach US$ 3,541.4 million by 2026, up from US$ 1,666.1 million in 2017, with a compound annual growth rate (CAGR) of 8.8% from 2018 to 2026. According to the research survey conducted by the International Journal of Impotence Research (IJIR), 30% of adult men throughout the globe suffer from premature ejaculation. The prevalence rate of premature ejaculation varies across geographical and sociocultural populations. Premature ejaculation has been understood to have a negative impact on the sexual satisfaction of men and their sexual partners.

People suffering from premature ejaculation are less likely to seek medical help, thus making it of utmost importance to raise awareness and acceptance of this disorder among patients and physicians. The existence of developed healthcare infrastructure and the rising prevalence of premature ejaculation disorder drive the market's growth in North America. The presence of a mature generic drug market and increasing awareness of premature ejaculation propel the market's growth in Asia-Pacific.

Market Synopsis

Impressive pharmacodynamic properties exerted by SSRIs make them the drug of the first choice for premature ejaculation treatment.

Selective serotonin reuptake inhibitors are prescribed as the first-line drug therapy for the treatment of premature ejaculation. The mechanism of action is delayed ejaculation due to limited serotonin reabsorption at presynaptic neuron cells and increased serotonin levels at postsynaptic receptors. The drugs prescribed as SSRIs are sertraline, paroxetine, fluoxetine, and citalopram. Topical anesthetic agents are set to project impressive growth during the forecast period of 2018 to 2026. Currently, FortacinTM, a eutectic mixture of Lidocaine and Prilocaine, is being used as a topical aerosol formulation to decrease the sensitivity of the glans penis and increase the intravaginal ejaculation latency time. The topical anesthetic agents have better patient compliance and excellent sexual satisfaction in patients suffering from premature ejaculation.

Faster onset of action and a low price make the oral route of administration popular among patients suffering from acute premature ejaculation.

Prescribed drugs such as SSRIs, tricyclic antidepressants, phosphodiesterase type 5 inhibitors, and beta-adrenergic blockers are taken by the oral route of administration. Quick response time and availability at a low price increase the popularity of the oral route among patients suffering from acute premature ejaculation. The topical route is to register magnificent growth during the forecast period of 2018–2026 due to better patient compliance and excellent climax control by delaying intravaginal ejaculation.

The rise in psychotropic drug use and a negative attitude toward sex drive Asia-Pacific market growth.

In the present scenario, North America holds the largest regional market in the premature ejaculation treatment market, with a 41.5% share. The rising incidence of relationship stress, depression, and anxiety in the younger population and the increasing number of people suffering from illicit drug abuse is responsible for premature ejaculation issues in North America. The domicile of market leaders such as GlaxoSmithKline Plc and Teva Pharmaceutical Industries Ltd. and adherence to effective treatment guidelines drive the premature ejaculation treatment market in Europe. Asia-Pacific serves as a lucrative market for premature ejaculation treatment. The factors responsible for the market's growth are the rise in psychotropic drug use and the lack of a constructive attitude towards sex. Latin America, the Middle East, and Africa will project moderate growth during the forecast period of 2018–2026 on account of developing healthcare infrastructure and rising public health awareness regarding premature ejaculation.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026,considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The latest market trends for the premature ejaculation treatment market were determined by quantitative analysis. The market segment comprises drug class, route of administration, and geography.

The premature ejaculation market comprises branded and generic drugs, which are prescribed according to the disease prognosis. Inorganic and organic market growth strategies are being employed by market leaders to generate revenue in the premature ejaculation treatment market. Quantitative analysis is a very useful tool for mapping the drivers, restraints, and opportunities prevalent in the premature ejaculation treatment market. A diverse product portfolio gives a better understanding of the competition prevalent in the market. The pharmaceutical companies commanding the premature ejaculation treatment market are Absorption Pharmaceuticals, AstraZeneca, Allergan Plc, Bayer AG, Eli Lilly & Company, GlaxoSmithKline Plc, Innovus Pharmaceuticals, Merck & Co., Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

Key questions are answered in this report.

  • Who are the market leaders steering the premature ejaculation treatment market?
  • What will be the compound annual growth rate and market estimation for the premature ejaculation treatment market?
  • What are the organic and inorganic market strategies adopted by key players?
  • What are the DROs for the premature ejaculation treatment market?
  • What is the disease prognosis, and how does it contribute to market growth?
  • Which is the leading and fastest-growing route of administration segment for the premature ejaculation treatment market?
  • Which is the largest and fastest-growing drug class segment for the premature ejaculation treatment market?
  • Which is the largest and fastest-growing regional segment for the premature ejaculation treatment market?
  • What drugs are being prescribed, and what treatment guidelines are postulated for the treatment of premature ejaculation?

Frequently Asked Question:

The market for Premature Ejaculation Treatment Market is expected to reach USD$ 3,541.4 Mn in 2026.

The Premature Ejaculation Treatment Market is expected to see significant CAGR growth over the coming years, at 8.8%.

The report is forecasted from 2018 -2026.

The base year of this report is 2017.

BAllergan Plc, Bayer AG, Eli Lilly & Company, GlaxoSmithKline Plc, Innovus Pharmaceuticals, Merck & Co., Inc., Pfizer, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Aug 2018
Category:  Pharmaceuticals
Report ID:   59268
Report Format:   PDF
Pages:   120
Rating:    4.5 (55)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support